Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review

References

• MalykhAGSadaieMRPiracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disordersDrugs20107028731220166767
   PubMed Web of Science ®Google Scholar
• AmentaFTayebatiSKPathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunctionCurr Med Chem20081548849818289004
   PubMed Web of Science ®Google Scholar
• BrownDAAcetylcholineBr J Pharmacol2006147Suppl 1S120S12616402095
   PubMed Web of Science ®Google Scholar
• TerryAVJrBuccafuscoJJThe cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug developmentJ Pharmacol Exp Ther200330682182712805474
   PubMed Web of Science ®Google Scholar
• AmentaFParnettiLGallaiVWallinATreatment of cognitive dysfunction associated with Alzheimer’s disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?Mech Ageing Dev20011222025204011589920
   PubMed Web of Science ®Google Scholar
• WellsGSheaBO’ConnellDThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysisOttawaOttawa Hospital Research Institute2011 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed October 7, 2012
   Google Scholar
• FediMReutensDDubeauFLong-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsyArch Neurol20015878178611346373
   PubMedGoogle Scholar
• WaegemansTWilsherCRDanniauAClinical efficacy of piracetam in cognitive impairment: a meta-analysisDement Geriatr Cogn Disord20021321722412006732
   PubMed Web of Science ®Google Scholar
• NickolsonVJWolthuisOLEffect of the acquisition-enhancing drug piracetam on rat cerebral energy metabolism: comparison with naftidrofuryl and methamphetamineBiochem Pharmacol19762522412244985556
   PubMed Web of Science ®Google Scholar
• GrauMMonteroJLBalaschJEffect of piracetam on electrocorticogram and local cerebral glucose utilization in the ratGen Pharmacol1987182052113569848
   PubMedGoogle Scholar
• FesenkoUAPiracetam improves children’s memory after general anaesthesiaAnestezjol Intens Ter2009411621 Polish19517672
   PubMedGoogle Scholar
• McKhannGMGoldsboroughMABorowiczLMJrCognitive outcome after coronary artery bypass: a one-year prospective studyAnn Thorac Surg1997635105159033329
   PubMed Web of Science ®Google Scholar
• BruggemansEFVan DijkJGHuysmansHAResidual cognitive dysfunctioning at 6 months following coronary artery bypass graft surgeryEur J Cardiothorac Surg199596366438751253
   PubMed Web of Science ®Google Scholar
• HolinskiSClausBAlaarajNCerebroprotective effect of piracetam in patients undergoing coronary bypass surgeryMed Sci Monit200814153157
   Web of Science ®Google Scholar
• SzalmaIKissAKardosLPiracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placeboAnn Thorac Surg2006821430143516996947
   PubMed Web of Science ®Google Scholar
• UebelhackRVohsKZytowskiMEffect of piracetam on cognitive performance in patients undergoing bypass surgeryPharmacopsychiatry200336899312806565
   PubMed Web of Science ®Google Scholar
• JelicVKivipeltoMWinbladBClinical trials in mild cognitive impairment: lessons for the futureJ Neurol Neurosurg Psychiatry20067742943816306154
   PubMed Web of Science ®Google Scholar
• HolinskiSClausBAlaarajNCerebroprotective effect of piracetam in patients undergoing open heart surgeryAnn Thorac Cardiovasc Surg20111713714221597409
   PubMed Web of Science ®Google Scholar
• LobaughNJKaraskovVRomboughVPiracetam therapy does not enhance cognitive functioning in children with Down syndromeArch Pediatr Adolesc Med200115544244811296070
   PubMedGoogle Scholar
• KesslerJThielAKarbeHPiracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patientsStroke2000312112211610978039
   PubMed Web of Science ®Google Scholar
• RozziniRZanettiOBianchettiATreatment of cognitive impairment secondary to degenerative dementia: effectiveness of oxiracetam therapyActa Neurol (Napoli)19931544528456595
   PubMedGoogle Scholar
• GreenRCGoldsteinFCAuchusAPTreatment trial of oxiracetam in Alzheimer’s diseaseArch Neurol199249113511361444879
   PubMed Web of Science ®Google Scholar
• ParnettiLAmentaFGallaiVCholine alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical dataMech Ageing Dev20011222041205511589921
   PubMed Web of Science ®Google Scholar
• ParnettiLMigniniFTomassoniDTrainiEAmentaFCholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?J Neurol Sci200725726426917331541
   PubMed Web of Science ®Google Scholar
• DominoEFMathewsBNTaitSKOrtizAEffects of oral phosphatidylcholine on mouse brain choline and acetylcholineArch Int Pharmacodyn Ther198326549546651405
   PubMedGoogle Scholar
• AdibhatlaRMHatcherJFDempseyRJCytidine-5′-diphosphocholine (CDP-choline) affects CTP: phosphocholine cytidylyl transferase and lysophosphatidylcholine after transient brain ischemiaJ Neurosci Res20047639039615079868
   PubMed Web of Science ®Google Scholar
• D’OrlandoKJSandageBWJrCiticoline (CDP-choline): mechanisms of action and effects in ischemic brain injuryNeurol Res1995172812847477743
   PubMed Web of Science ®Google Scholar
• AlvarezXACacabelosRSampedroCEfficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of cerebrolysinEur J Neurol201118596820500802
   PubMed Web of Science ®Google Scholar
• SecadesJJCiticoline: pharmacological and clinical reviewRev Neurol201052Suppl 2S1S62 Spanish21432836
   PubMed Web of Science ®Google Scholar
• FioravantiMYanagiMCytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderlyCochrane Database Syst Rev20042CD00026915106147
   PubMedGoogle Scholar
• RenshawPFBabbSMYurgelun-ToddDAWaldLLVillafuerteRACohenBMChronic citicholine (CDP-choline) administration alters brain phospholipid metabolites and improves cognitive performance in healthy, older adultsPresented at the 37th American College of Neuropsychopharmacology Annual MeetingSeptember 14–18, 1998San Juan, Puerto Rico
   Google Scholar
• AgnoliAFioravantiMLechnerHEfficacy of CDP choline in chronic cerebral vascular diseasesZappiaVKennedyEPNilssonBIGallettiPNovel Biochemical, Pharmacological and Clinical Aspects of CytidinediphosphocholineAmsterdamElsevier Science Publishing1985
   Google Scholar
• SinforianiETruccoMPacchettiCGualtieriSValutazione degli effetti della citicolina nella malattia cerebro-vascolare cronica [Evaluation of citicoline effects in cerebrovascular disease]Minerva Med1986775157 Italian3511406
   PubMedGoogle Scholar
• MottaLFicheraGTiralosiGDi StefanoALa citicolina nel trattamento delle cerebrovasculopatie croniche [Citicoline in the treatment of chronic cerebrovascular disease]G Gerontol198634149158 Italian
   Google Scholar
• TanakaYMinematsuKHiranoTHayashidaKYamaguchiTEffects of CDP-choline on dynamic changes in LCBF and cognitive function in demented subjects. An H2 15O-PET studyRinsho Shinkeigaku1994348778817820960
   PubMedGoogle Scholar
• CaamañoJGómezMJFrancoACacabelosREffects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s diseaseMethods Find Exp Clin Pharmacol1994162112187913981
   PubMedGoogle Scholar
• ValeSCurrent management of the cognitive dysfunction in Parkinson’s disease: how far have we come?Exp Biol Med (Maywood)200823394195118535172
   PubMed Web of Science ®Google Scholar
• DhimanRKChawlaYKMinimal hepatic encephalopathyIndian J Gastroenterol20092851619529896
   PubMedGoogle Scholar
• MalaguarneraMBellaRVacanteMAcetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathyScand J Gastroenterol20114675075921443422
   PubMed Web of Science ®Google Scholar
• MalaguarneraMGarganteMPCristaldiEAcetyl-L-carnitine treatment in minimal hepatic encephalopathyDig Dis Sci2008533018302518357530
   PubMed Web of Science ®Google Scholar
• SoczynskaJKKennedySHChowCSWoldeyohannesHOKonarskiJZMcIntyreRSAcetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?Expert Opin Investig Drugs200817827843
   PubMed Web of Science ®Google Scholar
• MalaguarneraMGarganteMPCristaldiEAcetyl L-carnitine (ALC) treatment in elderly patients with fatigueArch Gerontol Geriatr20084618119017658628
   PubMed Web of Science ®Google Scholar
• LiuJThe effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overviewNeurochem Res20083319420317605107
   PubMed Web of Science ®Google Scholar
• MancusoCBatesTEButterfieldDANatural antioxidants in Alzheimer’s diseaseExpert Opin Investig Drugs20071619211931
   PubMed Web of Science ®Google Scholar
• CagnonLBraissantOHyperammonemia-induced toxicity for the developing central nervous systemBrain Res Rev20075618319717881060
   PubMedGoogle Scholar
• AmentaFCarotenutoAFasanaroGLanariAReaRTrainiEPreliminary results of Ascomalva trial on the association of donepezil and choline alphoscerate in Alzheimer’s disease with associated cerebrovascular injuryG Gerontol2011598998 Italian
   Google Scholar
• MaloufRBirksJDonepezil for vascular cognitive impairmentCochrane Database Syst Rev20041CD00439514974068
   PubMedGoogle Scholar
• RomanGCVascular dementia revisited: diagnosis, pathogenesis, treatment, and preventionMed Clin N Am20028647749912168556
   PubMed Web of Science ®Google Scholar
• PantoniLTreatment of vascular dementia: evidence from trials with non-cholinergic drugsJ Neurol Sci2004226677015537523
   PubMed Web of Science ®Google Scholar
• Alvarez-SabínJRománGCCiticoline in vascular cognitive impairment and vascular dementia after strokeStroke201142Suppl 1S40S4321164117
   PubMed Web of Science ®Google Scholar
• García-CobosRFrank-GarcíaAGutiérrez-FernándezMDíez-TejedorECiticoline, use in cognitive decline: vascular and degenerativeJ Neurol Sci201029918819220875651
   PubMed Web of Science ®Google Scholar
• MuresanuDFAlvarezXAMoesslerHPersistence of the effects of cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension studyJ Neurol Sci201029917918320923712
   PubMed Web of Science ®Google Scholar
• GuekhtABMoesslerHNovakPHGusevEICerebrolysin InvestigatorsCerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trialJ Stroke Cerebrovasc Dis20112031031820656516
   PubMed Web of Science ®Google Scholar
• PloskerGLGauthierSCerebrolysin: a review of its use in dementiaDrugs Aging20092689391519848437
   PubMed Web of Science ®Google Scholar
• AkhondzadehSShafiee SabetMHarirchianMHToghaMA 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s diseasePsychopharmacology (Berl)201020763764319838862
   PubMed Web of Science ®Google Scholar
• Yurko-MauroKCognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive declineCurr Alzheimer Res2010719019620088810
   PubMed Web of Science ®Google Scholar
• SchaefferELForlenzaOVGattazWFPhospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer diseasePsychopharmacology (Berl)2009202375118853146
   PubMed Web of Science ®Google Scholar